Replies to post #474 on Lpath Inc fka LPTN

[happy1987]

In fact, I said so much useless ah, I hope there is good news in October, let us look at it. I will continue to hold

[happy1987]

Shares of Lpath, Inc. (NASDAQ:LPTN) appreciated by 14.72% during the past week but lost 2.71% on a 4-week basis. The shares have outperformed the S&P 500 by 11.1% in the past week but underperformed the index by 5.31% in the last 4 weeks.

Lpath, Inc. (NASDAQ:LPTN) rose 3.06% or 0.0065 points on Friday and made its way into the gainers of the day. After trading began at $0.217 the stock was seen hitting $0.22 as a peak level and $0.2009 as the lowest level. The stock ended up at $0.219. The daily volume was measured at 652,605 shares. The 52-week high of the share price is $3.751 and the 52-week low is $0.1804. The company has a market cap of $6.4 million.

Lpath Inc. has dropped 31.95% during the last 3-month period . Year-to-Date the stock performance stands at -92.23%.On a different note, The Company has disclosed insider buying and selling activities to the Securities Exchange, Petree Daniel H, director of Lpath, Inc had purchased 10,000 shares on December 12, 2014 in a transaction. The price per share was $2.78 and the total amount of the disclosed transaction was $27,800.The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing. This information is based on open market transaction at the market prices.



The company shares have dropped -92.72% from its 1 Year high price. On Mar 20, 2015, the shares registered one year high at $3.75 and the one year low was seen on Aug 24, 2015. The 50-Day Moving Average price is $0.22 and the 200 Day Moving Average price is recorded at $0.81.

Lpath, Inc. (Lpath) is a biotechnology company focused on the discovery and development of bio-active lipid-targeted monoclonal antibody (mAb) therapeutics. The Company has three product candidates, iSONEP, ASONEP and Lpathomab. The Companys program, iSONEP, is a mAb against Sphingosine-1-Phosphate (S1P). As of December 31, 2012, it was in phase-II clinical trials for wet Age-Related Macular Degeneration. The Company is also advancing ASONEP, the systemic formulation of the mAb to S1P. ASONEP has completed a phase-I clinical trial and is entering phase-II clinical trials in Renal Cell Carcinoma. Lpaths third product candidate, Lpathomab, is a mAb to the bioactive lipid, Lysophosphatidic Acid (LPA). The Company also applies its technology platform, ImmuneY2, to discovering mAbs to new bioactive lipid targets.